Overview: CD10 Immunohistochemistry TestIntroduction: The CD10 Immunohistochemistry Test detects CD10 protein to diagnose lymphomas or kidney tumors, causing swelling or pain. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected lymphoid or renal malignancies.
Other Names: CD10 IHC Assay, Lymphoma/Kidney Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD10 testing began in the 1980s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD10 to diagnose lymphomas or kidney tumors, guides treatment, and evaluates patients with swelling or pain.
Test Parameters: 1. CD10 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, pain, or renal symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, pain, hematuria, or family history of lymphomas or kidney tumors. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD10 in lymphoid or renal tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for lymphoma or kidney tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD10 staining suggests acute lymphoblastic leukemia, follicular lymphoma, or renal cell carcinoma, guiding treatment. Negative staining may require further marker testing.
Specialist Consultation: Consult a hematologist, oncologist, or nephrologist for result interpretation and treatment planning.
Additional Supporting Tests: BCL-2 IHC, PAX-8 IHC, or renal ultrasound to confirm lymphoma or kidney tumor diagnosis.
Test Limitations: Not specific to one malignancy; other tumors may express CD10. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; American Journal of Surgical Pathology, Weiss LM, 2022.
